Clinical Trial Update: A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists [Phase 1]

View source ↗

Summary

Phase 1 trial in healthy adult panelists evaluating the safety of the VNZ/TEZ/D-IVA fixed-dose combination has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED